Biopharma Vital Signs – Part 6: Advice for Emerging Biotechs - Poll - MDSpire

Biopharma Vital Signs – Part 6: Advice for Emerging Biotechs

Industry experts share practical advice for emerging biotech companies navigating development decisions, funding pressures, manufacturing strategy, partner selection, and the path toward commercial readiness

  • July 24, 2026

  • 13 min

Share

Original Source(s)

Biopharma Vital Signs – Part 6: Advice for Emerging Biotechs

  • July 24, 2026

Related Content

Skin Deep Survival

Peptidomics via LC-MS/MS links early skin immune maturation to recovery from chytrid fungus in common midwife toads  

  • July 23, 2026

  • 3 min
Oral Shigella Vaccine Hits 89% Efficacy in Challenge Trial

An investigational oral Shigella sonnei vaccine showed robust protection against shigellosis in a phase 2 controlled human infection trial.

Bringing it Home: Why We Switched to In-House WGS

Annette Kim shares her experience of a real-world clinical laboratory transition to whole-genome sequencing

  • July 24, 2026

  • 8 min